Glenmark Finds Canadian Ryaltris Partner
Deal With Bausch Health Follows Russian And European Advances
Executive Summary
Glenmark has struck the latest in a series of commercialization deals for its Ryaltris nasal spray in the form of a ten-year alliance with Bausch Health for the Canadian market.
You may also be interested in...
Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
Glenmark’s Ryaltris Close To Entry In Major Eastern Europe Market
Having divested a basket of allergy treatments in Russia and the CIS to Dr Reddy’s last year, Glenmark is gearing up to launch its novel Ryaltris nasal spray in a major Eastern Europe market.